3°C Saline Injection at the Duodenal Papilla to Prevent Post-ERCP Pancreatitis

NCT07381478 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2026-02-02

No results posted yet for this study

Summary

Endoscopic retrograde cholangiopancreatography (ERCP) is an endoscopic procedure used to diagnose and treat problems in the bile ducts and pancreas. One of its most common complications is \*\*post-ERCP pancreatitis\*\*. This multicenter randomized clinical trial will evaluate whether \*\*cooling the duodenal papilla\*\* with \*\*sterile saline at 3°C\*\* immediately after ERCP can reduce the risk of post-ERCP pancreatitis compared with standard ERCP care.

Adults \*\*≥18 years\*\* with a \*\*native papilla\*\* scheduled for diagnostic or therapeutic ERCP at \*\*three high-complexity university hospitals in Bogotá/Cundinamarca (Colombia)\*\* will be randomized \*\*1:1\*\* to: (1) \*\*intervention\*\*-instillation of \*\*250 mL\*\* of \*\*3°C sterile saline\*\* in \*\*five 50-mL aliquots\*\* directed to the papilla through the endoscope working channel at the end of ERCP, with aspiration between aliquots; or (2) \*\*control\*\*-standard ERCP with no additional instillation. The saline temperature will be verified immediately before administration. Standard preventive measures (e.g., rectal NSAIDs, lactated Ringer's hydration, prophylactic pancreatic stent when clinically indicated) may be used per usual care and will be recorded.

The \*\*primary outcome\*\* is post-ERCP pancreatitis at \*\*24 hours\*\*, defined using Cotton criteria (new/worsening abdominal pain plus serum amylase or lipase ≥3× the upper limit of normal). Secondary outcomes include pancreatitis severity, other ERCP-related complications, and safety through day 7 (including a telephone follow-up). Participants will be screened and consented before sedation; randomization occurs at the end of the ERCP; clinical assessment and labs are performed at 24 hours; follow-up continues through day 7.

Safety monitoring will include systematic assessment for potential effects related to local cooling (e.g., chills, duodenal spasm, mucosal bleeding at the instillation site, or clinically relevant hypothermia) at 2 and 24 hours, with surveillance for serious adverse events through day 7.

Conditions

Interventions

PROCEDURE

Topical Cold Sterile Saline Irrigation of the Duodenal Papilla (3°C)

250 mL of 3°C sterile saline administered in five 50-mL aliquots directed to the papilla via the endoscope working channel at ERCP completion, with aspiration between aliquots; saline temperature is verified immediately before administration

OTHER

Standard ERCP (Usual Care)

Standard ERCP performed with no additional saline instillation. Usual prophylaxis may be used when clinically indicated (e.g., rectal NSAIDs, lactated Ringer's hydration, prophylactic pancreatic stent in high-risk cases) and is recorded.

Sponsors & Collaborators

  • Hospital San Rafael de Facatativá

    collaborator UNKNOWN
  • Universidad Nacional de Colombia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2026-01-12
Completion
2026-01-14

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07381478 on ClinicalTrials.gov